Your browser doesn't support javascript.
loading
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
Jennings, Danna; Huntwork-Rodriguez, Sarah; Vissers, Maurits F J M; Daryani, Vinay M; Diaz, Dolores; Goo, Marisa S; Chen, John J; Maciuca, Romeo; Fraser, Kyle; Mabrouk, Omar S; van de Wetering de Rooij, Jeroen; Heuberger, Jules A A C; Groeneveld, Geert Jan; Borin, Marie T; Cruz-Herranz, Andrés; Graham, Danielle; Scearce-Levie, Kimberly; De Vicente, Javier; Henry, Anastasia G; Chin, Peter; Ho, Carole; Troyer, Matthew D.
Affiliation
  • Jennings D; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
  • Huntwork-Rodriguez S; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
  • Vissers MFJM; Centre for Human Drug Research, Leiden, the Netherlands.
  • Daryani VM; Department of Clinical Neuropharmacology, Leiden University Medical Center, Leiden, the Netherlands.
  • Diaz D; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
  • Goo MS; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
  • Chen JJ; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
  • Maciuca R; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
  • Fraser K; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
  • Mabrouk OS; Biogen Inc, Cambridge, Massachusetts, USA.
  • van de Wetering de Rooij J; Biogen Inc, Cambridge, Massachusetts, USA.
  • Heuberger JAAC; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
  • Groeneveld GJ; PRA Health Sciences, Groningen, the Netherlands.
  • Borin MT; Centre for Human Drug Research, Leiden, the Netherlands.
  • Cruz-Herranz A; Centre for Human Drug Research, Leiden, the Netherlands.
  • Graham D; Department of Clinical Neuropharmacology, Leiden University Medical Center, Leiden, the Netherlands.
  • Scearce-Levie K; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
  • De Vicente J; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
  • Henry AG; Biogen Inc, Cambridge, Massachusetts, USA.
  • Chin P; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
  • Ho C; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
  • Troyer MD; SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
Mov Disord ; 38(3): 386-398, 2023 03.
Article in En | MEDLINE | ID: mdl-36807624
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Parkinson Disease Type of study: Clinical_trials Limits: Humans Language: En Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Parkinson Disease Type of study: Clinical_trials Limits: Humans Language: En Year: 2023 Type: Article